Over 1,000 Chemotherapy Protocols And Counting

A Phase III Multi-center, Randomized, Open-label trial (NATALEE) Hormone Receptor-positive, HER2-negative Early Breast Cancer (Stage IIa-III) Ribociclib (400 mg/day) + ET (n=2549)

24 Jun

Prostate Cancer

New Indication: Talazoparib and Enzalutamide in Metastatic CRPC

Double-blind, placebo-controlled phase 3 trial (TALAPRO-2) Previously untreated, CRPC Enzalutamide + talazoparib (n=402) vs. Enzalutamide+ PBO (n=403

24 Jun

Renal Cell Carcinoma

New Protocol: Belzutifan and Cabozantinib for Advanced RCC

Phase II, single-arm, open-label, multicenter study Locally advanced or metastatic clear cell renal cell carcinoma had previously received immunotherapy and up to two systemic tre

24 Jun

Biliary Tract Cancer

New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer

Phase II, basket study (SGNTUC-019) Previously treated with and progressed after ≥1 line of systemic therapy for HER2-positive metastatic disease. Tucatinib (TUC) + Trastuzumab

24 Jun

Non-Small Cell Lung Cancer

New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

Phase II, single-arm study (PHAROS) Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC Encorafenib +Bininmetinib q28 (n=98)

24 Jun

GastroEsophageal Cancer

New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer

Open-label, multicenter, phase Ib/II trial HER2-positive advanced G/GEJ cancer that progressed from trastuzumab-containing first-line chemotherapy with fluoropyrimidine and platin

24 Jun

Hodgkin Lymphoma

New Protool: Nivolumab-AVD in Hodgkin Lymphoma

Phase III, randomized, controlled study (SWOG S1826) Previously untreated pts were ≥12 years (y) with stage 3-4 HL N-AVD (n=489) vs. BV-AVD (n=487)

20 May

Breast Cancer

New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer

Phase III, randomized, open-label trial (monarchE) Hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence Abemaciclib + ET (n=280

16 Mar

Nervous System Tumor

New Indication: Dabrafenib and Trametinib in bRAF V600E Mutant Glioma

Open-label, single-arm, phase 2, basket trial BRAFV600E mutation-positive high- low-grade glioma Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma Dabr

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries